X

Drug Profile

Research programme: cytokine receptor antagonists - Trillium Therapeutics Inc

Alternative Names: Cytokine receptor antagonists research programme - Trillium Therapeutics Inc

Latest Information Update: 29 Nov 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator St. Justine Hospital; University of Montreal
Developer Trillium Therapeutics
Class
Mechanism of Action Cytokine modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Discontinued Inflammation

Most Recent Events

17 Nov 2021 Trillium Therapeutics Inc has been acquired by Pfizer
12 Feb 2013 Discontinued - Preclinical for Inflammation in Canada (unspecified route)
29 May 2007 No development reported - Preclinical for Inflammation in Canada (unspecified route)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com